Abstract 18842: Prognostic Impacts of Metabolic Syndrome in Patients With Chronic Heart Failure -A Multicenter Prospective Cohort Study
Background: Metabolic syndrome (MetS) is a pathological condition with a clustering of metabolic components and is substantially associated with increased risk of atherosclerotic cardiovascular diseases. However, prognostic impacts of MetS in patients with chronic heart failure (CHF) remain to be fully elucidated.
Methods and Results: From the database of our nationwide, multicenter observational study with 10,464 CHF patients in stage A/B/C/D in Japan, 4,764 patients with Stage C/D CHF were enrolled. The prevalence of MetS, according to the Japanese standard diagnostic criteria, was 39.6% (48.7% in males and 20.5% in females), which was almost twice higher as compared with the general population in Japan. CHF patients with MetS were characterized by higher prevalence of male, obesity and lifestyle-related diseases, including diabetes mellitus, hypertension and hyperlipidemia. Although univariate Cox proportional hazard analysis revealed that MetS was not associated with increased incidence of composite of all-cause death and atherosclerotic cardiovascular events (unadjusted HR 0.92; 95% CI 0.81-1.04, P=0.177), multivariate analysis adjusted with body mass index (BMI) alone or fully adjusted with clinical backgrounds showed that MetS was associated with increased incidence of the composite endpoint (BMI-adjusted HR 1.33; 95% CI 1.15-1.55, P<0.001 and full-adjusted HR 1.24; 95% CI 1.05-1.46, P=0.013), particularly in males (BMI-adjusted HR 1.36; 95% CI 1.14-1.62, P<0.001, full-adjusted HR 1.31; 95% CI 1.08-1.59, P=0.005), but not in females (BMI-adjusted HR 1.20; 95% CI 0.86-1.67, P=0.287, full-adjusted HR 1.15; 95% CI 0.80-1.64, P=0.456). Interestingly, the adverse prognostic impacts of MetS were evident in males with BMI<25.0kg/m2, but not in those with BMI≥25.0kg/m2 (Table).
Conclusions: These results indicate that MetS is associated with worse prognosis in patients with Stage C/D CHF, particularly in male patients without obesity.
Author Disclosures: S. Tadaki: None. Y. Sakata: None. S. Miyata: None. M. Asakura: None. K. Shimada: None. T. Yamamoto: None. T. Kadokami: None. S. Yasuda: None. T. Miura: None. S. Ando: None. M. Yano: None. M. Kitakaze: None. H. Daida: None. H. Shimokawa: None.
- © 2015 by American Heart Association, Inc.